Vasculitis & polymyalgia rheumatica
Real-world avacopan use in ANCA-associated vasculitis: glucocorticoid exposure and healthcare resource utilization from US claims data
Authors' conclusion
In this real-world analysis, avacopan use was associated with reduced glucocorticoid exposure and lower HCRU over 12 months among patients who remained on treatment. These trends were also observed in patients aged 65+. Longer-term comparator studies are needed.
Study context
- Population
- Adults initiating avacopan for ANCA-associated vasculitis, including a sub-cohort aged 65+patients initiating avacopan (median age 55 years), 94 persistent on avacopan · age ≥ 65 years 53 · persistent on avacopan (primary cohort) 94 · 65+ sub-cohort (persistent) 25
- Participants
- 167 adults
- Exposure
- 12 months post-index vs pre-index among patients persistent on avacopan
- PRIMARY COHORTn = 94
- 65+ SUB-COHORTn = 25
- Outcome
- Mean prednisone-equivalent daily dose (PEDD)
- Follow-up
- 90 days pre-index to 12 months post-index
Methodological detailsMedicare Fee-for-Service and MORE2 Registry® databases, 12 months of continuous enrolment before and after index
- Medicare Fee-for-Service and MORE2 Registry® databases
- 12 months of continuous enrolment before and after index
Main finding
As reported in the abstract
Primary cohort: decreased from 12.6 mg/day to 5.1 mg/day
12.6 to 5.1 mg/day
65+ sub-cohort: decreased from 15.1 to 6.9 mg/day
15.1 to 6.9 mg/day
Observational data: associations, not effects.
Further findings
Proportion of patients with emergency department visits · 12 months
- Primary cohort: decreased from 62.8% to 39.4%
- 62.8% to 39.4%
- 65+ sub-cohort: declined from 60.0% at baseline to below reporting thresholds at follow-up
- 60.0%
Proportion of patients with inpatient admissions · 12 months
- Primary cohort: decreased from 55.3% to 21.3%
- 55.3% to 21.3%
- 65+ sub-cohort: declined from 68.0% at baseline to below reporting thresholds at follow-up
- 68.0%
Original publication
Real-world avacopan use in ANCA-associated vasculitis: glucocorticoid exposure and healthcare resource utilization from US claims data. Rheumatology (Oxford). Published 14 November 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →